Search
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigationalmRNA-1283 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant lineage JN.1. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875]. … Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S..
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … In clinical studies, patients treated with remestemcel-L demonstrated an improvement in their aGvHD and improved survival rates at subsequent days following intravenous infusion [L11022].
Categories: Complex MixturesMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalFDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalIt is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.
Categories: Complex MixturesNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial
go.drugbank.com/bio_entities/BE0000191TargetEnzymeHumansCore subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor … Essential for the catalytic activity and assembly of complex I (PubMed:14729820, PubMed:24028823, PubMed:30140060)
Synonyms: Complex I-30kDNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial
go.drugbank.com/bio_entities/BE0000729TargetEnzymeHumansEssential for the catalytic activity of complex I (PubMed:22036843, PubMed:30922174). Essential for the assembly of complex I (By similarity). … Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor
Synonyms: Complex I-49kDProtein SLC31A2
go.drugbank.com/bio_entities/BE0003662TransporterHumansDoes not function as a copper(1+) importer in vivo (By similarity). However, in vitro functions as a low-affinity copper(1+) importer (PubMed:17617060, PubMed:17944601). … export and modulates the copper and cisplatin accumulation via SLC31A1 (By similarity)
Synonyms: Copper transporter 2Function: copper ion transmembrane transporter activityCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.
Categories: Compounds used in a research, industrial, or household settingTicagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.